Regeneron Pharmaceuticals Inc
SWB:RGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Regeneron Pharmaceuticals Inc
SWB:RGO
|
US |
|
V
|
Valterra Platinum Ltd
JSE:VAL
|
ZA |
|
F
|
Fuelcell Energy Inc
SWB:FEY
|
US |
Intrinsic Value
The intrinsic value of 
Regeneron Pharmaceuticals Inc (RGO) under the Base Case is 84.43 EUR per share.
Compared with the current market price of 129.11 EUR, the stock appears
Overvalued by 35% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Regeneron Pharmaceuticals Does
Regeneron Pharmaceuticals makes prescription medicines, mostly biologic drugs that are built from antibodies and other protein-based therapies. It develops treatments for eye diseases, allergies, inflammation, cancer, and rare genetic disorders, then sells them through hospitals, clinics, pharmacies, and specialty distributors. Its main customers are patients and the doctors and health systems that treat them, along with insurers and government health programs that pay for the drugs.
- Headquarters
- United States of America US
- Employees
- 15 410
- IPO date
- Apr 2, 1991
Regeneron Pharmaceuticals has a narrow economic moat
Legal protection for medicines such as Dupixent and EYLEA HD prevents rivals from freely copying them, helping Regeneron preserve sales and profits. This protection covers specific medicines rather than whole treatment markets, where competing drugs remain available.
Read the full moat analysis
Revenue & Expenses Breakdown
Regeneron Pharmaceuticals Inc
Earnings Waterfall
Regeneron Pharmaceuticals Inc
The intrinsic value for Regeneron Pharmaceuticals Inc (RGO) under the Base Case is 84.43 EUR.
Compared with the current market price of 129.11 EUR, the stock appears Overvalued by 35% .